NASDAQ$OCUL
Ocular Therapeutix Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Ocular Therapeutix reported Q4 2020 financial results and provided a business update.
Ocular Therapeutix reported a net product revenue of $7.4 million for Q4 2020, a 25% sequential increase over the third quarter. DEXTENZA net product revenue was $6.9 million, a 28% sequential increase. The company's cash and cash equivalents were $228.1 million as of December 31, 2020.
- In-market purchases of DEXTENZA exceeded 14,000 billable units, representing sequential quarterly growth of greater than 40%.
- Interim data from the Phase 1 clinical trial of OTX-TKI showed preliminary biological activity with a decrease in retinal fluid.
- Interim data from the Phase 1 clinical trial of OTX-TIC showed a mean reduction in intraocular pressure from baseline of 7-11 mm Hg.
- The FDA has set an action date of October 18, 2021, for the sNDA for DEXTENZA allergic conjunctivitis.
Headline financials
Revenue & EPS history
Ocular Therapeutix · Revenue · Quarterly
$7.35M
Revenue by segment
Ocular Therapeutix · $6.9M total across 1 segment · Q4 2020
- Product Revenue$6.9M+331.3%100.0%
Forward guidance
Based on current plans, existing cash and cash equivalents as of December 31, 2020, will enable the Company to fund planned operating expenses, debt service obligations, and capital expenditure requirements through 2023.
Headwinds
- The cash guidance is subject to a number of assumptions including those related to the severity and duration of the COVID-19 pandemic.
- The cash guidance is subject to revenues and expenses associated with the commercialization of DEXTENZA.
- The cash guidance is subject to the pace of research and clinical development programs.
- The cash guidance is subject to other aspects of the business.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2020
-2.3%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+5.2%
Avg return
30 days after
33%
14 / 43 earnings
Positive
+24.0%
Q3 2016
Best reaction
-20.4%
Q3 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.7% | -1.2% | -10.0% | |
| Q3 2025 | -4.4% | -4.9% | +8.9% | |
| Q1 2025 | -12.4% | -19.8% | -4.8% | |
| Q4 2024 | +9.6% | +27.3% | +18.1% | |
| Q3 2024 | -13.6% | -15.8% | -18.0% | |
| Q2 2024 | +1.8% | +1.3% | +6.3% | |
| Q1 2024 | -0.9% | -2.4% | -10.3% | |
| Q4 2023 | -6.9% | -5.2% | -20.7% | |
| Q3 2023 | -10.7% | -23.7% | +34.8% | |
| Q2 2023 | -13.7% | -3.5% | -13.7% | |
| Q1 2023 | +4.8% | -0.6% | +18.6% | |
| Q4 2022 | -0.6% | -17.6% | -16.8% | |
| Q3 2022 | -9.7% | -6.6% | -20.0% | |
| Q2 2022 | -1.0% | +10.5% | +18.5% | |
| Q1 2022 | -4.3% | -5.5% | +12.4% | |
| Q4 2021 | -0.4% | -10.7% | -8.5% | |
| Q3 2021 | +9.5% | +0.0% | -2.9% | |
| Q2 2021 | +4.4% | +2.2% | +1.6% | |
| Q1 2021 | -5.1% | -9.4% | -13.3% | |
| Q4 2020 | +6.0% | -2.1% | -16.0% | |
| Q3 2020 | +6.6% | +11.1% | +68.8% | |
| Q2 2020 | +0.0% | -2.6% | -8.7% | |
| Q1 2020 | -1.7% | -4.8% | +9.0% | |
| Q4 2019 | -11.4% | +47.3% | +1.5% | |
| Q3 2019 | -5.5% | -4.4% | +38.2% | |
| Q2 2019 | -9.5% | -6.9% | -5.6% | |
| Q1 2019 | -4.6% | -1.6% | -9.0% | |
| Q4 2018 | -0.2% | +1.4% | +3.3% | |
| Q3 2018 | +8.0% | +1.0% | +11.1% | |
| Q2 2018 | +8.7% | +14.5% | +23.2% | |
| Q1 2018 | +0.3% | +6.4% | +7.7% | |
| Q4 2017 | -0.8% | +6.4% | +2.7% | |
| Q3 2017 | -13.7% | -12.1% | -34.4% | |
| Q2 2017 | -4.3% | -1.5% | +13.9% | |
| Q1 2017 | -11.3% | -9.9% | +20.9% | |
| Q4 2016 | -1.6% | +0.5% | -5.6% | |
| Q3 2016 | +24.0% | +42.9% | +77.3% | |
| Q2 2016 | -4.4% | +11.0% | +18.3% | |
| Q1 2016 | -8.0% | — | — | |
| Q4 2015 | +2.4% | — | — | |
| Q3 2015 | -20.4% | — | — | |
| Q2 2015 | -12.2% | — | — | |
| Q1 2015 | — | — | — | |
| Q3 2014 | +5.6% | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro